骨巨细胞瘤可以打狄诺塞麦吗？

(Denosumab) is mainly used to treat giant cell tumors of bone in adults and skeletally mature adolescents. Its indications include patients who cannot be surgically resected or whose surgical resection may cause severe disability and metastasis. It can also be used for metastatic cancer and osteoporosis.

Giant cell tumor of bone typically occurs in adults between the ages of 20 and 40 years. In most cases, giant cell tumors of bone do not spread to other parts of the body, but they can impair normal bone growth, causing pain, limited range of motion, and fractures. Rarely, giant cell tumor of bone can transform into a malignant tumor that can spread to the lungs if not treated promptly.

Denosumab (denosumab) is a fully humanized monoclonal antibody (IgG2 monoclonal antibody) that specifically targets receptor activator of nuclear factor-κB ligand (RANKL). It prevents RANKL from binding to its receptor substances, inhibits osteoclast activation and development, reduces bone resorption, and increases bone density. It can effectively inhibit multinucleated giant cells in giant cell tumors of bone. After a certain period of use, imaging assessments increase bone formation, and pathological examination shows that the number of multinucleated giant cells is significantly reduced or disappears).

A Phase II clinical trial before the FDA approved denosumab (denosumab) for the treatment of giant cell tumor of bone showed that 163 patients had no significant disease progression after an average of 10 months of follow-up. Another phase II clinical trial showed that among 100 patients who were likely to suffer severe disability if treated with surgery, 74% avoided surgery. Among 26 patients who underwent surgery, 16 had significantly less disability after surgery than expected before surgery.

Common side effects of denosumab include joint pain, headache, nausea, fatigue, back, and pain in the hands and feet. The most common serious side effects are osteonecrosis of the jaw and osteomyelitis (inflammation or bone infection). Because of the potential harm to the fetus, women of childbearing potential must use highly effective contraception when using this drug. These side effects will be reflected in the drug package insert, and patients will be informed in advance before injection.

Recommended related hot articles: /newsDetail/77960.html